Literature DB >> 10749568

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

J P Morello1, A Salahpour, A Laperrière, V Bernier, M F Arthus, M Lonergan, U Petäjä-Repo, S Angers, D Morin, D G Bichet, M Bouvier.   

Abstract

Over 150 mutations within the coding sequence of the V2 vasopressin receptor (V2R) gene are known to cause nephrogenic diabetes insipidus (NDI). A large number of these mutant receptors fail to fold properly and therefore are not routed to the cell surface. Here we show that selective, nonpeptidic V2R antagonists dramatically increase cell-surface expression and rescue the function of 8 mutant NDI-V2Rs by promoting their proper folding and maturation. A cell-impermeant V2R antagonist could not mimic these effects and was unable to block the rescue mediated by a permeant agent, indicating that the nonpeptidic antagonists act intracellularly, presumably by binding to and stabilizing partially folded mutants. In addition to opening new therapeutic avenues for NDI patients, these data demonstrate that by binding to newly synthesized mutant receptors, small ligands can act as pharmacological chaperones, promoting the proper folding and maturation of receptors and their targeting to the cell surface.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749568      PMCID: PMC377482          DOI: 10.1172/JCI8688

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

Authors:  M J Smit; R Leurs; A E Alewijnse; J Blauw; G P Van Nieuw Amerongen; Y Van De Vrede; E Roovers; H Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities.

Authors:  D Morin; N Cotte; M N Balestre; B Mouillac; M Manning; C Breton; C Barberis
Journal:  FEBS Lett       Date:  1998-12-28       Impact factor: 4.124

3.  5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.

Authors:  J D Albright; M F Reich; E G Delos Santos; J P Dusza; F W Sum; A M Venkatesan; J Coupet; P S Chan; X Ru; H Mazandarani; T Bailey
Journal:  J Med Chem       Date:  1998-07-02       Impact factor: 7.446

4.  Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.

Authors:  A Oksche; R Schülein; C Rutz; U Liebenhoff; J Dickson; H Müller; M Birnbaumer; W Rosenthal
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

5.  Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones.

Authors:  B K Tamarappoo; A S Verkman
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

6.  Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation.

Authors:  N Singh; G Zanusso; S G Chen; H Fujioka; S Richardson; P Gambetti; R B Petersen
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor.

Authors:  R Schülein; C Rutz; W Rosenthal
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

8.  Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.

Authors:  H Sadeghi; G L Robertson; D G Bichet; G Innamorati; M Birnbaumer
Journal:  Mol Endocrinol       Date:  1997-11

9.  Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype.

Authors:  Y Ala; D Morin; B Mouillac; N Sabatier; R Vargas; N Cotte; M Déchaux; C Antignac; M F Arthus; M Lonergan; M S Turner; M N Balestre; G Alonso; M Hibert; C Barberis; G N Hendy; D G Bichet; S Jard
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

10.  Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.

Authors:  T Schoneberg; J Yun; D Wenkert; J Wess
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

View more
  140 in total

Review 1.  Antagonists to the rescue.

Authors:  W J Welch; M Howard
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 3.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

4.  Alpha(1)-Antitrypsin Deficiency.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-12

5.  A missense LAMB2 mutation causes congenital nephrotic syndrome by impairing laminin secretion.

Authors:  Ying Maggie Chen; Yamato Kikkawa; Jeffrey H Miner
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 6.  Genetics of vasopressin receptors.

Authors:  Marc Thibonnier
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 7.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

8.  GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

Authors:  Randa S Eshaq; Letha D Stahl; Randolph Stone; Sheryl S Smith; Lucy C Robinson; Nancy J Leidenheimer
Journal:  Brain Res       Date:  2010-05-16       Impact factor: 3.252

9.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

10.  Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.

Authors:  Sayali A Ranadive; Baran Ersoy; Helene Favre; Clement C Cheung; Stephen M Rosenthal; Walter L Miller; Christian Vaisse
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.